Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT01109524

Public ClinicalTrials.gov record NCT01109524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 13, 2026, 11:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Cisplatin and Vinorelbine in Combination With Cetuximab as First Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): a Single Arm Multicenter Safety Phase 2 Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.

Study identification

NCT ID
NCT01109524
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
72 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2010
Primary completion
Aug 31, 2012
Completion
Aug 31, 2012
Last update posted
Dec 23, 2015

2010 – 2012

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
Donald W. Hill M.D., P.C. Casa Grande Arizona 85122
Beverly Hills Cancer Center Beverly Hills California 90211
Cancer Care Institute Los Angeles California 90036
Northern California Hematology & Oncology Oakland California 94609
Sharp Clinical Oncology Research San Diego California 92123
Broward Oncology Associates, P.A. Fort Lauderdale Florida 33308
Elite Research Institute Miami Florida 33125
Edward H. Kaplan, MD & Associates Skokie Illinois 60076
Fairview Southdale Medical Oncology Clinic Edina Minnesota 55435
Mid Dakota Clinic, Pc Bismarck North Dakota 58501
Temple University Hospital Philadelphia Pennsylvania 19140
University Medical Center Lubbock Texas 79415
Columbia Basin Hematology and Oncology Kennewick Washington 99336

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01109524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 23, 2015 · Synced Sep 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01109524 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →